Syndax Pharmaceuticals (SNDX) Cost of Revenue (2024 - 2026)

Syndax Pharmaceuticals' Cost of Revenue history runs 3 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 1238.53% year-over-year to $11.8 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 145.0% increase from a year earlier, with the FY2025 full-year figure at $7.0 million, up 743.83% from the prior year.
• Cost of Revenue grew to $11.8 million in Q1 2026 per SNDX's latest filing, from -$17.2 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $11.8 million in Q1 2026 and bottomed at -$17.2 million in Q4 2025.
• The 3-year median for Cost of Revenue is $1.1 million (2025), against an average of $983833.3.
• Across the five-year window, Cost of Revenue sank 2184.26% in 2025 and soared 1238.53% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $826000.0 in 2024, then sank by 2184.26% to -$17.2 million in 2025, then jumped by 168.81% to $11.8 million in 2026.
• Per Business Quant, the three latest SNDX Cost of Revenue figures stand at $11.8 million (Q1 2026), -$17.2 million (Q4 2025), and $8.3 million (Q3 2025).